VLST cancer, autoimmune, inflammation news

VLST said it would reduce headcount by 12 (70%) to five by year end to focus on cancer compound CP-870,893, which it licensed from Pfizer Inc. (NYSE:PFE, New York, N.Y.) in August. The anti- CD40 mAb has completed five Phase I trials. VLST expects to start additional Phase Ib or Phase IIa testing next half. The company said it has not chosen an indication, but would "probably" start in pancreatic cancer (see BioCentury, Sept. 3). ...